Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jul, 2016 | Pages:
59 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Ligand Pharmaceuticals, Inc. - Product Pipeline Review - 2016 Summary Global Markets Direct's, 'Ligand Pharmaceuticals, Inc. - Product Pipeline Review - 2016', provides an overview of the Ligand Pharmaceuticals, Inc.'s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Ligand Pharmaceuticals, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the pipeline therapeutic landscape of Ligand Pharmaceuticals, Inc. - The report provides overview of Ligand Pharmaceuticals, Inc. including its business description, key facts, and locations and subsidiaries - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report assesses Ligand Pharmaceuticals, Inc.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report features Ligand Pharmaceuticals, Inc.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects Reasons To Buy - Evaluate Ligand Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Ligand Pharmaceuticals, Inc. - Identify potential new clients or partners in the target demographic - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Ligand Pharmaceuticals, Inc.'s pipeline depth and focus of pipeline therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Ligand Pharmaceuticals, Inc. Snapshot 6 Ligand Pharmaceuticals, Inc. Overview 6 Key Information 6 Key Facts 6 Ligand Pharmaceuticals, Inc. - Research and Development Overview 7 Key Therapeutic Areas 7 Ligand Pharmaceuticals, Inc. - Pipeline Review 10 Pipeline Products by Stage of Development 10 Pipeline Products - Monotherapy 11 Pipeline Products - Partnered Products 12 Partnered Products/Combination Treatment Modalities 13 Pipeline Products - Out-Licensed Products 16 Out-Licensed Products/Combination Treatment Modalities 17 Ligand Pharmaceuticals, Inc. - Pipeline Products Glance 19 Ligand Pharmaceuticals, Inc. - Late Stage Pipeline Products 19 Pre-Registration Products/Combination Treatment Modalities 19 Phase III Products/Combination Treatment Modalities 20 Ligand Pharmaceuticals, Inc. - Clinical Stage Pipeline Products 21 Phase II Products/Combination Treatment Modalities 21 Phase I Products/Combination Treatment Modalities 22 Ligand Pharmaceuticals, Inc. - Early Stage Pipeline Products 23 Preclinical Products/Combination Treatment Modalities 23 Ligand Pharmaceuticals, Inc. - Drug Profiles 24 lasofoxifene tartrate 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 clopidogrel bisulfate 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 aplindore fumarate 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 pradefovir mesylate 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 MB-07133 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 LGD-6972 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 Drug to Inhibit JAK3 for Inflammation 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 LG-7455 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 LGD-3437 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 LGD-7501 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 PS-031291 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 Small Molecule to Antagonize CCR1 for Oncology 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 Small Molecule to Antagonize CRTH2 for Inflammation and Respiratory Diseases 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 Small Molecules to Activate Glucokinase for Type 2 Diabetes 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 Ligand Pharmaceuticals, Inc. - Pipeline Analysis 40 Ligand Pharmaceuticals, Inc. - Pipeline Products by Target 40 Ligand Pharmaceuticals, Inc. - Pipeline Products by Route of Administration 42 Ligand Pharmaceuticals, Inc. - Pipeline Products by Molecule Type 43 Ligand Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action 44 Ligand Pharmaceuticals, Inc. - Recent Pipeline Updates 46 Ligand Pharmaceuticals, Inc. - Dormant Projects 51 Ligand Pharmaceuticals, Inc. - Discontinued Pipeline Products 52 Discontinued Pipeline Product Profiles 52 adipiplon 52 clopidogrel bisulfate 52 LGD-5552 52 managlinat dialanetil 52 NGD-2000-1 53 NGD-91-1 53 NGD-91-2 53 NGD-91-3 53 NGD-94-1 53 NGD-94-4 53 NGD-96-1 53 NGD-97-1 53 Vanilloid Receptor-1 Program 54 Ligand Pharmaceuticals, Inc. - Company Statement 55 Ligand Pharmaceuticals, Inc. - Locations And Subsidiaries 56 Head Office 56 Other Locations & Subsidiaries 56 Appendix 58 Methodology 58 Coverage 58 Secondary Research 58 Primary Research 58 Expert Panel Validation 58 Contact Us 58 Disclaimer 59
List of Tables
Ligand Pharmaceuticals, Inc., Key Information 6 Ligand Pharmaceuticals, Inc., Key Facts 6 Ligand Pharmaceuticals, Inc. - Pipeline by Indication, 2016 8 Ligand Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2016 10 Ligand Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2016 11 Ligand Pharmaceuticals, Inc. - Partnered Products in Pipeline, 2016 12 Ligand Pharmaceuticals, Inc. - Partnered Products/ Combination Treatment Modalities, 2016 13 Ligand Pharmaceuticals, Inc. - Out-Licensed Products in Pipeline, 2016 16 Ligand Pharmaceuticals, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2016 17 Ligand Pharmaceuticals, Inc. - Pre-Registration, 2016 19 Ligand Pharmaceuticals, Inc. - Phase III, 2016 20 Ligand Pharmaceuticals, Inc. - Phase II, 2016 21 Ligand Pharmaceuticals, Inc. - Phase I, 2016 22 Ligand Pharmaceuticals, Inc. - Preclinical, 2016 23 Ligand Pharmaceuticals, Inc. - Pipeline by Target, 2016 40 Ligand Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2016 42 Ligand Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2016 43 Ligand Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2016 44 Ligand Pharmaceuticals, Inc. - Recent Pipeline Updates, 2016 46 Ligand Pharmaceuticals, Inc. - Dormant Developmental Projects,2016 51 Ligand Pharmaceuticals, Inc. - Discontinued Pipeline Products, 2016 52 Ligand Pharmaceuticals, Inc., Subsidiaries 56
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
